These combinations showed synergistic antitumoral effects in all five KRAS-G12C mutant cancer models in 2D in vitro experiments and the findings were recapitulated in lung adenocarcinoma 3D models in vitro and in xenografts in vivo. This evidence concerns the gene KRAS and cancer.